Publications by authors named "Michael Case"

Claim this Profile
I
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
Carol Wysham, Harpreet S Bajaj, Stefano Del Prato, Denise Reis Franco, Arihiro Kiyosue, Michael Case

N Engl J Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Solanezumab in Preclinical Alzheimer's Disease.
Reisa A Sperling, Michael C Donohue, Rema Raman, Michael S Rafii, Keith Johnson, Michael Case

N Engl J Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying climate change refugia to forest management and old-growth restoration.
Kavya Pradhan, Ailene K Ettinger, Michael J Case, Janneke Hille Ris Lambers

Glob Chang Biol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced fire severity offers near-term buffer to climate-driven declines in conifer resilience across the western United States.
Kimberley T Davis, Marcos D Robles, Kerry B Kemp, Philip E Higuera, Teresa Chapman, Michael J Case

Proc Natl Acad Sci U S A· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates.
Alette M Wessels, Dorene M Rentz, Michael Case, Steve Lauzon, John R Sims

Alzheimers Dement (N Y)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia.
Diana Otero Svaldi, Ixavier A Higgins, Karen C Holdridge, Roy Yaari, Michael Case

Alzheimers Dement (N Y)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging the potential of nature to meet net zero greenhouse gas emissions in Washington State.
James C Robertson, Kristina V Randrup, Emily R Howe, Michael J Case, Phillip S Levin

PeerJ· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant.
Erin G Doty, John H Krege, Gerhardt Pohl, Michael Case, Sherie A Dowsett

Headache· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol.
Max Tsai, Michael Case, Paul Ardayfio, Helen Hochstetler, Darren Wilbraham

Clin Pharmacol Drug Dev· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
Jan Lewis Brandes, Suzanne Klise, John H Krege, Michael Case, Rashna Khanna

Cephalalgia· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
Li Shen Loo, Brian M Plato, Ira M Turner, Michael G Case, Joel Raskin

BMC Neurol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Peter J Goadsby, Linda A Wietecha, Ellen B Dennehy, Bernice Kuca, Michael G Case

Brain· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease.
Adam J Schwarz, Karen L Sundell, Arnaud Charil, Michael G Case, Ralf K Jaeger

Alzheimers Dement (N Y)· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Climate change impacts on the distribution of the allergenic plant, common ragweed (Ambrosia artemisiifolia) in the eastern United States.
Michael J Case, Kristina A Stinson

PLoS One· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical Functioning Among Patients Aging With Human Immunodeficiency Virus (HIV) Versus HIV Uninfected: Feasibility of Using the Short Physical Performance Battery in Clinical Care of People Living With HIV Aged 50 or Older.
Heidi M Crane, Michael E Miller, June Pierce, Amanda L Willig, Michael Lloyd Case

Open Forum Infect Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia.
Brian A Willis, Karen Sundell, D Richard Lachno, Lisa R Ferguson-Sells, Michael G Case

Alzheimers Dement (N Y)· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical properties of continuous composite scales and implications for drug development.
Hong Liu-Seifert, Scott Andersen, Michael Case, JonDavid Sparks, Karen C Holdridge

J Biopharm Stat· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Lawrence S Honig, Bruno Vellas, Michael Woodward, Mercè Boada, Roger Bullock, Michael Case

N Engl J Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating mechanistic and empirical model projections to assess climate impacts on tree species distributions in northwestern North America.
Michael J Case, Joshua J Lawler

Glob Chang Biol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia.
Elisabeth K Degenhardt, Michael M Witte, Michael G Case, Peng Yu, David B Henley

Psychosomatics· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.
Helen Hochstetler, Paula T Trzepacz, Shufang Wang, Peng Yu, Michael Case

J Alzheimers Dis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.
Christopher Carlson, Eric Siemers, Ann Hake, Michael Case, Roza Hayduk

Alzheimers Dement (Amst)· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Eric R Siemers, Karen L Sundell, Christopher Carlson, Michael Case, Gopalan Sethuraman

Alzheimers Dement· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Ann Hake, Paula T Trzepacz, Shufang Wang, Peng Yu, Michael Case

Alzheimers Dement· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate Alzheimer's disease dementia.
Michael M Witte, Paula Trzepacz, Michael Case, Peng Yu, Helen Hochstetler

J Neuropsychiatry Clin Neurosci· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis